drug–device combination products are more complex. The regulations are more demanding. The opportunity is bigger than ever.
#CombinationProducts #MedicalDevices #Pharma #RegulatoryStrategy #DigitalHealth #ClinicalResearch

https://genelifecr.blogspot.com/2026/05/drugdevice-combination-products.html

In 2012, Genelife published a perspective on drug–device combination products.

The conclusion then: the benefits justify the complexity. The manufacturing model that made most sense: two distinct facilities, coordinated but separate.

Our updated perspective — what's changed, what hasn't, and what it means for your program — is now on the blog.

#DrugDeviceCombination #CombinationProducts #MedicalDevices #ClinicalResearch #RegulatoryStrategy #Pharma #DigitalHealth



https://genelifecr.blogspot.com/2026/05/drugdevice-combination-products.html